dc.check.date	2022-10-03T09:00:44Z
dc.check.embargoformat	Both hard copy thesis and e-thesis	en
dc.check.entireThesis	Entire Thesis Restricted
dc.check.info	Restricted to everyone for five years	en
dc.check.opt-out	Not applicable	en
dc.check.reason	Releasing this thesis would cause substantial prejudice to the commercial interests of University College Cork	en
dc.contributor.advisor	Cotter, Paul	en
dc.contributor.advisor	Guinane, Caitriona	en
dc.contributor.advisor	Hill, Colin	en
dc.contributor.advisor	Ross, R. Paul	en
dc.contributor.author	Hegarty, James William
dc.contributor.funder	Science Foundation Ireland	en
dc.contributor.funder	Teagasc	en
dc.date.accessioned	2017-10-04T09:00:44Z
dc.date.issued	2017
dc.date.submitted	2017
dc.description.abstract	Obesity is a complex syndrome associated with a number of serious implications for human health. The gut microbiota in obesity and related metabolic conditions has received considerable attention. The aim of this project was to (1) harness the bacteriocin-producing capacity of the gut and (2) develop a bacteriocin-producing probiotic that can contribute to the prevention/treatment of obesity and related metabolic disorders. Firstly, bacteriocin production among a selection of commercial probiotic products was examined. This investigation suggests that the commercial bacteriocin-producing probiotics are not very heterogeneous and that bacteriocin production is not being optimally harnessed as a probiotic trait. To identify strains with activity against obesity-associated targets, a culture-based screen was undertaken. Four lead bacteriocin-producing isolates were identified which successfully inhibited species enriched in type 2 diabetic patients. DPC6988 was selected for further investigation. We next investigated the impact of the bacteriocin-producing DPC6988, and another nonproducing control strain, on gut microbial populations using an ex vivo model of the distal colon. Although both strains altered microbial populations over the 24 hr fermentation period, a number of beneficial changes were attributed to DPC6988 only. Finally, the ability of DPC6988 to alter the gut microbiota and mitigate the metabolic abnormalities with respect to obesity in a DIO mouse model was examined. Despite alterations to the gut microbiota, treatment with this strain did not result in improvements to weight gain or metabolic health. Overall this thesis resulted in the identification of a number of baceriocin-producing gut microbes. Further work with DPC6988 will be necessary to understand the extent to which this strain can contribute to the prevention/treatment of obesity and related disorders and, more generally, to optimally harness the ability of bacteriocin-producing strains to beneficially change the composition of the gut microbiota.	en
dc.description.sponsorship	Teagasc (Teagasc Walsh Fellowship)	en
dc.description.status	Not peer reviewed	en
dc.description.version	Accepted Version
dc.format.mimetype	application/pdf	en
dc.identifier.citation	Hegarty, J. W. 2017. Harnessing the bacteriocin-producing capacity of the gut with a view to controlling microorganisms that have been associated with obesity and related metabolic disorders. PhD Thesis, University College Cork.	en
dc.identifier.endpage	188	en
dc.identifier.uri	https://hdl.handle.net/10468/4824
dc.language.iso	en	en
dc.publisher	University College Cork	en
dc.relation.project	info:eu-repo/grantAgreement/SFI/SFI Principal Investigator Programme (PI)/11/PI/1137/IE/Obesibiotics/	en
dc.rights	© 2017, James William Hegarty.	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/	en
dc.subject	Probiotic	en
dc.subject	Bacteriocin	en
dc.subject	Obesity	en
dc.subject	Gut microbiota	en
dc.thesis.opt-out	false
dc.title	Harnessing the bacteriocin-producing capacity of the gut with a view to controlling microorganisms that have been associated with obesity and related metabolic disorders	en
dc.type	Doctoral thesis	en
dc.type.qualificationlevel	Doctoral	en
dc.type.qualificationname	PhD (Science)	en
ucc.workflow.supervisor	c.hill@ucc.ie

Harnessing the bacteriocin-producing capacity of the gut with a view to controlling microorganisms that have been associated with obesity and related metabolic disorders

Files

Original bundle

License bundle

Collections